Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | ODC1 | P11926 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL10619788 | 1.00 | HRH4 (0.41) | HRH4HRH3ODC1CA12CA1 | |
| Trifluoroacetic Acid SCHEMBL11052838 | 0.97 | HRH4 (0.40) | HRH4HRH3ODC1CA12CA1 | |
| Trifluoroacetic Acid SCHEMBL6490887 | 0.88 | HRH4 (0.50) | HRH4HRH3ODC1CA12CA1 | |
| Trifluoroacetic Acid SCHEMBL10619767 | 0.88 | ODC1 (0.48) | HRH4HRH3ODC1CA12CA1 | |
| Trifluoroacetic Acid SCHEMBL1833664 | 0.88 | TSHR (0.47) | HRH4HRH3ODC1CA12CA1 | |
| Trifluoroacetic Acid SCHEMBL3149196 | 0.88 | ODC1 (0.48) | HRH4HRH3ODC1CA12CA1 | |
| Trifluoroacetic Acid SCHEMBL29019099 | 0.87 | GABRR1 (0.41) | HRH4HRH3ODC1CA12CA1 | |
| Trifluoroacetic Acid SCHEMBL28235039 | 0.86 | ALDH1A1 (0.38) | ODC1CA2SMN1; SMN2THRBTSHR | |
| Diaminooctane SCHEMBL31657050 | 0.85 | MEN1 (0.52) | HRH4HRH3ODC1CA12CA1 | |
| Trifluoroacetic Acid SCHEMBL31657036 | 0.85 | MEN1 (0.52) | HRH4HRH3ODC1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115915795-A | Perovskite solar cell containing double-layer trifluoroacetate modification layer and preparation method thereof | 河北工业大学 | 2023-04-04 | — | — | CN | claimed |
| CN-1606439-A | Cis-imidazolines | HOFFMANN LA ROCHE (CH) | 2005-04-13 | — | — | CN | claimed |
| CN-115915795-A | Perovskite solar cell containing double-layer trifluoroacetate modification layer and preparation method thereof | 河北工业大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-115915795-A | Perovskite solar cell containing double-layer trifluoroacetate modification layer and preparation method thereof | 河北工业大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-109265400-B | Arginine methyltransferase inhibitors and uses thereof | EPIZYME股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-111093645-A | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2020-05-01 | — | — | CN | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| EP-2012759-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| EP-1841768-B1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| WO-2007121923-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| EP-1841768-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006074925-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| EP-1458378-B1 | AMINO ACID DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2006-05-24 | — | — | EP | disclosed |
| CN-1606439-A | Cis-imidazolines | HOFFMANN LA ROCHE (CH) | 2005-04-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | HRH4 496/4885HRH3 628/4885ODC1 898/4885 |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | HRH4 1867/4885HRH3 2710/4885ODC1 1991/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | HRH4 181/4885HRH3 318/4885ODC1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.